Samsung Epis Holdings
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Samsung Epis Holdings is a biotech-focused holding company, a structure where one entity owns and oversees subsidiary businesses, whose main subsidiary, Samsung Bioepis, develops and commercialises biosimilars: lower-cost versions of complex biological medicines used to treat autoimmune, oncological, eye, blood, and bone diseases.
Those biosimilar medicines reach patients and healthcare systems across major markets including the United States, Europe, Canada, Australia, Brazil, and Japan. Listed on KOSPI, Korea's main stock exchange, the company derives the overwhelming majority of its revenue from biosimilar product sales.
Summary is AI-generated and may contain errors · figures from DART filings
Samsung Epis Holdings is structured as a formal holding company under Korea's Monopoly Regulation and Fair Trade Act, with two subsidiaries: Samsung Bioepis and Epis NexLab.
Samsung Epis Holdings in five facts
What does Samsung Epis Holdings do?
Samsung Epis Holdings is a biotech-focused holding company, a structure where one entity owns and oversees subsidiary businesses, whose main subsidiary, Samsung Bioepis, develops and commercialises biosimilars: lower-cost versions of complex biological medicines used to treat autoimmune, oncological, eye, blood, and bone diseases.
Where is Samsung Epis Holdings listed and in which sector?
Samsung Epis Holdings (Korean name: 삼성에피스홀딩스) trades under KRX code 0126Z0 on KOSPI, the main board of the Korea Exchange. It is classified in the Financials sector, Diversified Financials.
How large is Samsung Epis Holdings?
Its market capitalisation was US$6.3B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Samsung Epis Holdings's latest annual revenue and operating profit?
For fiscal year 2025, Samsung Epis Holdings reported revenue of US$190M, operating profit of US$11.4M and net income of US$64.4M, per its annual report on DART (data retrieved from DART on 2026-10-02).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Clarification of rumor or media report (unconfirmed) (subsidiary)Oct 21
- Earnings release schedule notice (notice)Oct 14
- Change in shares held by the largest shareholderOct 6
- DisclosureOct 1
- [Amended] Corporate governance reportSep 28
- Change in shares held by the largest shareholderSep 7
- [quarterly, individual company] Large business group status disclosureAug 31
- Operating results (consolidated) (preliminary) (fair disclosure)
Samsung Epis Holdings filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$266M, operating profit of US$39.8M and net income of US$58.2M.
Earnings · Jul 24 - Operating results (consolidated) (preliminary) (fair disclosure) (subsidiary)
Samsung Epis Holdings filed a subsidiary's provisional (unaudited) consolidated results for Q2 2026: revenue of US$266M (−2.2% year on year), operating profit of US$58.7M (−3.6% year on year) and net income of US$72.4M (+72.1% year on year).
Earnings · Jul 24 - Operating results (consolidated) (preliminary) (fair disclosure)
Samsung Epis Holdings filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$307M, operating profit of US$61.2M and net income of US$67.2M.
Earnings · Apr 23 - Operating results (consolidated) (preliminary) (fair disclosure) (subsidiary)
Samsung Epis Holdings filed a subsidiary's provisional (unaudited) consolidated results for Q1 2026: revenue of US$307M (+13.6% year on year), operating profit of US$97.3M (+12.6% year on year) and net income of US$94.3M (+21.8% year on year).
Earnings · Apr 23 - Operating results (consolidated) (preliminary) (fair disclosure)Earnings · Jan 26
- Operating results (consolidated) (preliminary) (fair disclosure) (subsidiary)Earnings · Jan 26